DAA therapy and ADAMTS13/VWF for HCV

DAA therapy and ADAMTS13/VWF for HCV - DAA therapy and ADAMTS13/VWF for HCV

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036835

Enrollment

Registered

2020-01-01

Start date

2020-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatitis type C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)> 20 years old 2)The patients obtained the consent

Exclusion criteria

Exclusion criteria: 1)The impossible of oral intake 2)The pharmacokinetics is changed for patient's condition 3)The necessary medicine change the pharmacokinetics of rifaximin 4)The pregnancy and lactating 5)The allergy of rifaximin 6)The outcome evaluation is difficult for patient's condition 7)The execution plan of achievement is difficult

Design outcomes

Primary

Measure	Time frame
Portal hypertension	—

Countries

Japan

Contacts

Public ContactHiroaki Hiroaki

Nara medical unversity 3rd departemnt of interanal medicine

htky@naramed-u.ac.jp0744223051

Outcome results